A new trading day began on Monday, with Adaptive Biotechnologies Corp (NASDAQ: ADPT) stock price up 3.15% from the previous day of trading, before settling in for the closing price of $7.47. ADPT’s price has ranged from $2.28 to $9.01 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 17.92% over the last five years. Meanwhile, its annual earnings per share averaged 14.71%. With a float of $141.74 million, this company’s outstanding shares have now reached $147.77 million.
The firm has a total of 619 workers. Let’s measure their productivity. In terms of profitability, gross margin is 58.17%, operating margin of -86.43%, and the pretax margin is -89.17%.
Adaptive Biotechnologies Corp (ADPT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adaptive Biotechnologies Corp is 4.61%, while institutional ownership is 92.58%. The most recent insider transaction that took place on Mar 24 ’25, was worth 15,282. In this transaction Chief Scientific Officer of this company sold 1,698 shares at a rate of $9.00, taking the stock ownership to the 1,279,524 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Officer proposed sale 1,698 for $8.66, making the entire transaction worth $14,705.
Adaptive Biotechnologies Corp (ADPT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 14.71% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.67% during the next five years compared to -1.51% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Here are Adaptive Biotechnologies Corp’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.08, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.70 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Analysing the last 5-days average volume posted by the [Adaptive Biotechnologies Corp, ADPT], we can find that recorded value of 2.72 million was better than the volume posted last year of 1.86 million. As of the previous 9 days, the stock’s Stochastic %D was 36.41%. Additionally, its Average True Range was 0.72.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 72.36%, which indicates a significant increase from 43.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.50% in the past 14 days, which was lower than the 84.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.87, while its 200-day Moving Average is $5.77. Now, the first resistance to watch is $8.32. This is followed by the second major resistance level at $8.95. The third major resistance level sits at $9.75. If the price goes on to break the first support level at $6.89, it is likely to go to the next support level at $6.09. Should the price break the second support level, the third support level stands at $5.46.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
With a market capitalization of 1.14 billion, the company has a total of 148,582K Shares Outstanding. Currently, annual sales are 178,960 K while annual income is -159,490 K. The company’s previous quarter sales were 47,460 K while its latest quarter income was -33,690 K.
